Results 141 to 150 of about 8,212 (230)

Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment. [PDF]

Molecules
Liang X, Du M, Wang J, Lei X, Tian Y, Zhang X.   +5 more
europepmc   +1 more source

Posttranslational Modifications of p62/SQSTM1 in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
Schematic illustration of p62 as a posttranslational modifications (PTMs)‐programmed integrator in homeostasis, pathogenesis, and therapeutic targeting. (Left) Homeostasis: In physiological states, p62, through various PTMs such as phosphorylation, ubiquitination, and acetylation, coordinates essential cellular functions.
Weikai Wang, Xin Jiang, Runing Qiu, Chandra Sugiarto Wijaya, Miaoqin Chen, Jin Wang, Liyuan Zhu, Hongchuan Jin, Lifeng Feng   +8 more
wiley   +1 more source

PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives. [PDF]

Pharmaceuticals (Basel)
Degennaro P, Ghafir El Idrissi I, Purgatorio R, Fanizzi A, Rullo M, Pisani L, Macchia E, Torsi L, Stefanachi A, Leonetti F.   +9 more
europepmc   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer. [PDF]

Curr Issues Mol Biol
Saruhan S, Özdemir D, Ağca CA.
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation

MedComm, Volume 7, Issue 10, October 2026.
In vivo CAR‐T cell generation directly engineers endogenous T cells using pre‐manufactured gene delivery vectors that target T cells and deliver CAR‐encoding genetic material. The resulting CAR‐T cells expand in vivo and mediate antigen‐specific cytotoxicity.
Zhenxin Bai, Ming Yi, Shengtao Hu, Dixuan Xue, Luxin Wei, Lifeng Zhang, Zhijun Dai   +6 more
wiley   +1 more source

Exosome-Mediated Delivery of PROTACs for Targeted Protein Degradation in Cancer, Neurodegenerative, Infectious, and Inflammatory Diseases. [PDF]

J Cell Mol Med
Ghosh SB, Banerjee R, Almohaimeed HM, Almars AI, ALMatrafi TA, Saleh FM, Mohammedsaleh ZM, Ealla KKR, Kumer A, Dhara B.   +9 more
europepmc   +1 more source

KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine

MedComm, Volume 7, Issue 10, October 2026.
KRAS‐mutant cancers are therapeutically shaped by both allele identity and tumor context. Direct KRAS inhibition has achieved the greatest clinical success in KRAS G12C‐mutant NSCLC, whereas colorectal cancer often requires EGFR cotargeting and pancreatic cancer remains constrained by stromal and metabolic barriers. Shared resistance mechanisms include
Jiaying Cai, Yimin Wu, Xing Jia, Li Yang, Wenjun Yang, Weishan Lu, Zhiye Huang, Yang Pan, Zixuan Fei, Junnan Ru, Jiazheng Zhao, Jue Shen, Taobo Luo, Da Chen, Haihong Yu, Haihan Deng, Jian Zeng, Wenmei Jiang, Leilei Wu   +18 more
wiley   +1 more source

Context matters in PROTAC design: navigating the trade-off between degradation and developability. [PDF]

J Enzyme Inhib Med Chem
Zhang B, Zhang Y, Zhang B, Hu J, Ke C, Wu T, Wei M, Xia J, Wang M, Zhao Q, Tian L, Liang C.   +11 more
europepmc   +1 more source